Premium
Public–Private Partnerships in Lead Discovery: Overview and Case Studies
Author(s) -
Gottwald Matthias,
Becker Andreas,
Bahr Inke,
MuellerFahrnow Anke
Publication year - 2016
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201600078
Subject(s) - general partnership , identification (biology) , drug discovery , pharmaceutical industry , process (computing) , lead (geology) , risk analysis (engineering) , drug development , business , process management , management science , knowledge management , computer science , engineering , data science , medicine , drug , pharmacology , bioinformatics , biology , paleontology , botany , finance , operating system
The pharmaceutical industry is faced with significant challenges in its efforts to discover new drugs that address unmet medical needs. Safety concerns and lack of efficacy are the two main technical reasons for attrition. Improved early research tools including predictive in silico , in vitro , and in vivo models, as well as a deeper understanding of the disease biology, therefore have the potential to improve success rates. The combination of internal activities with external collaborations in line with the interests and needs of all partners is a successful approach to foster innovation and to meet the challenges. Collaboration can take place in different ways, depending on the requirements of the participants. In this review, the value of public–private partnership approaches will be discussed, using examples from the Innovative Medicines Initiative (IMI). These examples describe consortia approaches to develop tools and processes for improving target identification and validation, as well as lead identification and optimization. The project “Kinetics for Drug Discovery” (K4DD), focusing on the adoption of drug–target binding kinetics analysis in the drug discovery decision‐making process, is described in more detail.